From: Gab2 plays a carcinogenic role in ovarian cancer by regulating CrkII
 | N | Gab2 expression | CrkII expression | ||||
---|---|---|---|---|---|---|---|
Low | High | P Value | Low | High | P Value | ||
Age | Â | Â | Â | 0.404 | Â | Â | 0.694 |
 < 57 | 55 | 23 | 32 |  | 11 | 44 |  |
 ≥ 57 | 64 | 22 | 42 |  | 11 | 53 |  |
Menopause | Â | Â | Â | 0.885 | Â | Â | 0.454 |
NO | 23 | 9 | 14 | Â | 3 | 20 | Â |
Yes | 96 | 36 | 60 | Â | 19 | 77 | Â |
FIGO stage | Â | Â | Â | 0.023 | Â | Â | 0.049 |
I-II | 31 | 17 | 14 | Â | 12 | 19 | Â |
III-IV | 88 | 28 | 60 | Â | 10 | 78 | Â |
Histological subtype | Â | Â | 0.054 | Â | Â | 0.563 | |
Serous | 102 | 35 | 67 | Â | 18 | 84 | Â |
Non-serous | 17 | 10 | 7 | Â | 4 | 13 | Â |
Grade | Â | Â | 0.001 | Â | Â | 0.001 | |
Low-grade | 14 | 11 | 3 | Â | 7 | 7 | Â |
High-grade | 105 | 34 | 71 | Â | 15 | 90 | Â |
Ascites | Â | Â | Â | 0.404 | Â | Â | 0.180 |
No | 55 | 23 | 32 | Â | 13 | 42 | Â |
Yes | 64 | 22 | 42 | Â | 9 | 55 | Â |
Treatment | Â | Â | Â | 0.697 | Â | Â | 0.040 |
PDS | 42 | 17 | 25 | Â | 12 | 30 | Â |
NACT + IDS | 77 | 28 | 49 |  | 10 | 67 |  |
Platinum resistance |  |  |  < 0.001 |  |  |  < 0.001 | |
NO | 72 | 43 | 29 | Â | 20 | 52 | Â |
Yes | 47 | 2 | 45 | Â | 2 | 45 | Â |
Resistance and progression | 0.594 | Â | Â | 0.898 | |||
NO | 10 | 3 | 7 | Â | 2 | 8 | Â |
Yes | 109 | 42 | 67 | Â | 20 | 89 | Â |
lymph node metastasis | Â | Â | 0.840 | Â | Â | 0.958 | |
No | 86 | 33 | 53 | Â | 16 | 70 | Â |
Yes | 33 | 12 | 21 | Â | 6 | 27 | Â |